Leyden Labs Lands €20 Million EIB Investment Facilitated by HERA to Advance Pandemic Preparedness Activities

Leyden Labs Lands €20 Million EIB Investment Facilitated by HERA to Advance Pandemic Preparedness Activities

LUXEMBOURG & LEIDEN, the Netherlands--(BUSINESS WIRE)--Jun 3, 2025-

Dutch-based Leyden Labs secures €20M from EIB

Dutch-based Leyden Laboratories BV, a clinical-stage biotech company, announced that it has signed a €20M venture debt financing from the European Investment Bank (EIB). The funding will support the development of Leyden Labs’ antibody programmes aimed at countering viral infections. The company’s lead programme, a nasal spray known as PanFlu, is in clinical development. It targets influenza viruses, including Avian Flu (H5), and is intended for…

EIB and Leyden Labs Secure €20 Million Financing to Advance Pandemic Preparedness with Innovative Nasal Spray

EIB and Leyden Labs Secure €20 Million Financing to Advance Pandemic Preparedness with Innovative Nasal Spray (IN BRIEF) The European Investment Bank (EIB) has signed a €20 million financing deal with Leyden Laboratories to support the development of its innovative pan-influenza nasal spray, which aims to protect against seasonal and pandemic viral infections. The funding, guaranteed by the European Commission’s InvestEU initiative under the Hea…